Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling

In this episode, an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.